Related references
Note: Only part of the references are listed.Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer
Rebeca Gonzalez-Pastor et al.
CANCER GENE THERAPY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
G. K. Friedman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
Premal H. Thaker et al.
CLINICAL CANCER RESEARCH (2021)
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Hillard M. Lazarus et al.
FRONTIERS IN IMMUNOLOGY (2021)
Clinical Application of Cytokines in Cancer Immunotherapy
Yi Qiu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
A. Algazi et al.
ANNALS OF ONCOLOGY (2020)
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies
Leander Huyghe et al.
EMBO MOLECULAR MEDICINE (2020)
Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
Elizabeth C. Eckert et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Rebecca C. Arend et al.
GYNECOLOGIC ONCOLOGY (2020)
Tolerizing Strategies for the Treatment of Autoimmune Diseases: From ex vivo to in vivo Strategies
Anje Cauwels et al.
FRONTIERS IN IMMUNOLOGY (2020)
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How et al.
CANCERS (2020)
Cytokines in oncolytic virotherapy
Jonathan G. Pol et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2019)
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
Steven S. Raman et al.
IMMUNOTHERAPY (2019)
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al.
LANCET ONCOLOGY (2019)
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Marijo Bilusic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
Nanoparticles in the clinic: An update
Aaron C. Anselmo et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2019)
Impact of silver, gold, and iron oxide nanoparticles on cellular response to tumor necrosis factor
Kamil Brzoska et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2018)
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
Riikka Havunen et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study
Premal H. Thaker et al.
GYNECOLOGIC ONCOLOGY (2017)
Chitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice
Lunmei Tan et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych et al.
PLOS ONE (2017)
On-Body Injector An administration device for pegfilgrastim
Linda J. Mahler et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2017)
Intralesional treatment of metastatic melanoma: a review of therapeutic options
Benjamin Weide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Talimogene Laherparepvec: First Global Approval
Sarah L. Greig
DRUGS (2016)
CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
Zuqiang Liu et al.
ONCOIMMUNOLOGY (2016)
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
Lily Francis et al.
ONCOTARGET (2016)
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
PEGylation in anti-cancer therapy: An overview
Prajna Mishra et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Delivery of human NKG2D-IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity
Chen Yan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
CAR therapy: the CD19 paradigm
Michel Sadelain
JOURNAL OF CLINICAL INVESTIGATION (2015)
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Elizabeth Buchbinder et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Improved stability and efficacy of chitosan/pDNA complexes for gene delivery
Noemi Cifani et al.
BIOTECHNOLOGY LETTERS (2015)
Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor
Bin Hu et al.
DRUG DELIVERY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Interferon-Tau Attenuates Uptake of Nanoparticles and Secretion of Interleukin-1β in Macrophages
Kyoko Hara et al.
PLOS ONE (2014)
Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12
Qiongming Xu et al.
BIOMATERIALS (2012)
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
Jason Park et al.
NATURE MATERIALS (2012)
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer
Michael S. Sabel et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure
Ryo Suzuki et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Historical insights into cytokines
Charles A. Dinarello
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer
JG Fewell et al.
JOURNAL OF CONTROLLED RELEASE (2005)
A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor
A Bex et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
The design and development of pegfilgrastim (PEG-rmetHuG-CSF, neulasta((R)))
G Molineux
CURRENT PHARMACEUTICAL DESIGN (2004)
IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma
ML Lucas et al.
MOLECULAR THERAPY (2002)
Tumor rejection by disturbing tumor stroma cell interactions
S Ibe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
